Western Alliance reports 10.9% CET1 capital ratio for third quarter 2026
Bitget2026/11/09 20:46- Western Alliance's third-quarter 2026 Basel III report showed capital above well-capitalized thresholds as of September 30.
- The common equity Tier 1 ratio stood at 10.9%, versus a 7% minimum including the capital conservation buffer.
- Total capital ratio reached 14%; the Tier 1 capital ratio was 11.9%.
- A 5.9% capital conservation buffer exceeded the 2.5% requirement, avoiding restrictions on capital distributions or discretionary bonuses.
- Total regulatory capital stood at $9.5 billion against $67.76 billion in risk-weighted assets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
